Ranibizumab for the treatment of neovascular AMD

International Journal of Clinical Practice

Volumn 61, Issue 3, 2007, Pages 501-509

  Kaiser, P K ^a   Do, Diana V ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 013958; ANECORTAVE; ANGIOGENESIS INHIBITOR; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; BEVASIRANIB SODIUM; EVIZON; FLUOROURACIL; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SIRNA 027; SQUALAMINE LACTATE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CELL GROWTH FACTOR TRAP; VASCULOTROPIN A; VATALANIB;

ADVERSE OUTCOME; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BLINDNESS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROL GROUP; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOPHTHALMITIS; GROUPS BY AGE; HUMAN; INCIDENCE; MULTIPLE CYCLE TREATMENT; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TREATMENT OUTCOME; UVEITIS; VISION; VISUAL IMPAIRMENT;

AGED; ANTIBODIES, MONOCLONAL; HUMANS; MACULAR DEGENERATION; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847062459     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01299.x     Document Type: Article

References (58)

1. Friedman DS, O'Colmain BJ, Munoz B et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-72.
2. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-36.
3. Ferris FL, Davis MD, Clemons TE et al. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol 2005; 123: 1570-4.
4. Schmidt S, Haines JL, Postel EA et al. Joint effects of smoking history and APOE genotypes in age-related macular degeneration. Mol Vis 2005; 11: 941-9.
5. Edwards AO, Ritter R III, Abel KJ et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4.
6. Gold B, Merriam JE, Zernant J et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006; 38: 458-62.
7. Rakic JM, Lambert V, Devy L et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3186-93.
8. Kvanta A, Algvere PV, Berglin L et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-34.
9. Kliffen M, Sharma HS, Mooy CM et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81: 154-62.
10. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999; 117: 1329-45.
11. Oner A, Karakucuk S, Mirza E, Erkilic K. Electrooculography after photodynamic therapy. Doc Ophthalmol 2005; 111: 83-6.
12. Ozdemir H, Karacorlu SA, Karacorlu M. Early optical coherence tomography changes after photodynamic therapy in patients with age-related macular degeneration. Am J Ophthalmol 2006; 141: 574-6.
13. Tzekov R, Lin T, Zhang KM et al. Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci 2006; 47: 377-85.
14. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-60.
15. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638-45.
16. Ergun E, Maar N, Ansari-Shahrezaei S et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 2006; 142: 10-6.
17. Sutter FK, Kurz-Levin MM, Fleischhauer J et al. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin Monatsbl Augenheilkd 2006; 223: 376-8.
18. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143-52.
19. Ruckman J, Green LS, Beeson J et al. 2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998; 273: 20556-67.
20. Gragoudas ES, Adamis AP, Cunningham ET Jr et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
21. Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25: 815-27.
22. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
23. Leung DW, Cachianes G, KuangWJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
24. Olofsson B, Korpelainen E, Pepper MS et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-14.
25. Nozaki M, Sakurai E, Raisler BJ et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest 2006; 116: 422-9.
26. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
27. Senger DR, Connolly DT, Van deWater L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50: 1774-8.
28. Ding XM, Mao BY, Jiang S et al. Neuroprotective effect of exogenous vascular endothelial growth factor on rat spinal cord neurons in vitro hypoxia. Chin Med J (Engl) 2005; 118: 1644-50.
29. Yourey PA, Gohari S, Su JL, Alderson RF. Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci 2000; 20: 6781-8.
30. Soker S, Takashima S, Miao HQ et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-45.
31. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109: 227-41.
32. Keyt BA, Berleau LT, Nguyen HV et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-95.
33. Houck KA, Ferrara N, Winer J et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806-14.
34. Lei J, Jiang A, Pei D. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1998; 1443: 400-6.
35. Zhang HT, Scott PA, Morbidelli L et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000; 83: 63-8.
36. Lebherz C, Maguire AM, Auricchio A et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes 2005; 54: 1141-9.
37. Adamis AP, Shima DT, Tolentino MJ et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71.
38. Akiyama H, Mohamedali K, Lima-Silva R et al. Vascular targeting of ocular neovascularization with a VEGF121/gelonin chimeric protein. Mol Pharmacol 2005; 68: 1543-50.
39. Krzystolik MG, Afshari MA, Adamis AP et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338-46.
40. Oshima Y, Oshima S, Nambu H et al. Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol 2004; 201: 393-400.
41. Hera R, Keramidas M, Peoc'h M et al. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol 2005; 139: 589-96.
42. Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-47.
43. Nguyen QD, Shah S, Tatlipinar S et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368-70.
44. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-5.
45. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-9.
46. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363.e5-72.
47. Maier P, Unsoeld AS, Junker B et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005; 243: 593-600.
48. Slakter JS, Bochow TW, D'Amico DJ et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113: 3-13.
49. Lucentis (ranibizumab injection). [Prescribing Information]. South San Francisco, CA: Genentech, Inc, 2006.
50. Kim KJ, Li B, Houck K et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7: 53-64.
51. Chen Y, Wiesmann C, Fuh G et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 93: 865-81.
52. Gaudreault J, Fei D, Rusit J et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-33.
53. Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005; 112: 1048-53.
54. Rosenfeld PJ, Heier JS, Hantsbarger G et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 632.
55. Heier JS, Antoszyk AN, Pavan PR et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113: 642.e1-4.
56. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
57. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
58. Heier JS, Boyer DS, Ciulla TA et al. Ranibizumab in combination with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 1 results. Arch Ophthalmol 2006; 124: 1532-42.